Get the Stockscreener App
19.57
0.41%
-0.08
After Hours:
19.57
Syndax Pharmaceuticals Inc stock is traded at $19.57, with a volume of 1.44M.
It is down -0.41% in the last 24 hours and down -5.96% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$19.65
Open:
$19.7
24h Volume:
1.44M
Relative Volume:
0.82
Market Cap:
$1.75B
Revenue:
$217.42M
Net Income/Loss:
$-243.25M
P/E Ratio:
-7.0013
EPS:
-2.7952
Net Cash Flow:
$-278.35M
1W Performance:
-0.96%
1M Performance:
-5.96%
6M Performance:
-4.68%
1Y Performance:
+20.50%
1-Day Range:
$19.17
$19.87
1-Week Range:
$19.17
$20.88
52-Week Range:
$12.99
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.57 | 1.76B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | H.C. Wainwright | Buy |
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
SNDX Maintained by UBS -- Price Target Lowered to $33 - GuruFocus
UBS lowers Syndax Pharmaceuticals price target on revenue outlook By Investing.com - Investing.com Canada
Syndax (SNDX) Q2 2026 Earnings Call Transcript - AOL.com
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Eastern Progress
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Eastern Progress
Syndax (SNDX) Quarterly Results: Profit Per Share Falls Below Its Benchmark in the Reported Period; Trading Move - vinanet.vn
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Syndax Pharmaceuticals (SNDX) Edges Up 0.46% to $19.85 as Range-Bound Trading PersistsHigh Low Breadth - vinanet.vn
GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
SNDX Stock Price, Quote & Chart - ChartMill
The Technical Signals Behind (SNDX) That Institutions Follow - Stock Traders Daily
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall? - Yahoo Finance
SNDX Maintained by JP Morgan -- Price Target Lowered to $40.00 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Syndax Pharmaceuticals (SNDX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX - marketbeat.com
Net margin % of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Long term debt to total assets ratio of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Total common shares outstanding of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Price to sales forward of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
State Street Corporation (SNDX) discloses 5.66M-share, 6.4% holding in Syndax - Stock Titan
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors - Yahoo Finance
Syndax Pharmaceuticals Inc (1T3) Q3 2024 Earnings ReportResults, Call & Slides - tipranks.com
Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st
HC Wainwright Brokers Decrease Earnings Estimates for SNDX - MarketBeat
Syndax Pharmaceuticals Inc (1T3) Q1 2024 Earnings ReportResults, Call & Slides - tipranks.com
Surging Revenue And Narrower Losses Might Change The Case For Investing In Syndax Pharmaceuticals (SNDX) - webull.com
What is HC Wainwright's Estimate for SNDX FY2029 Earnings? - MarketBeat
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $26 to $57 - Moomoo
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Five New Syndax Employees Receive Stock Options With 4-Year Vesting - Stock Titan
Syndax Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-08-05 - Seeking Alpha
Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $38.27, Implies 101% Upside - TradingView
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down on Disappointing Earnings - MarketBeat
SNDX Maintains Rating by HC Wainwright & Co. -- Price Target Low - GuruFocus
HC Wainwright Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - marketbeat.com
Sei Investments Co. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highli - GuruFocus
SNDX Q2 2026 Sales Surge Highlights Growth Potential Despite Val - GuruFocus
Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highlights: Revenue Surges 92% as ... - Yahoo! Finance Canada
SNDX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Syndax Pharmaceuticals Q2 Earnings Call Highlights - marketbeat.com
Syndax Pharmaceuticals (SNDX) Q2 Revenue Miss Highlights Valuati - GuruFocus
Is Syndax Pharmaceuticals Inc (SNDX) Facing Value Challenges Aft - GuruFocus
SNDX: Q2 revenue surged 92% year-over-year, driven by strong Revuforj and Niktimvo growth - TradingView
Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results - MarketBeat
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):